Dysregulated bile acid (BA)/lipid metabolism and gut bacteria dysbiosis are tightly
associated with the development of obesity and non-alcoholic fatty liver disease (NAFLD) …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent chronic liver disease
for which no approved therapies are available. Despite intensive research, the cellular …

Background and Aims NAFLD represents an increasing health problem in association with
obesity and diabetes with no effective pharmacotherapies. Growing evidence suggests that …

Hepatic lipogenesis is normally tightly regulated but is aberrantly elevated in obesity.
Fibroblast Growth Factor-15/19 (mouse FGF15, human FGF19) are bile acid-induced late …

Nonalcoholic fatty liver disease (NAFLD), a chronic condition associated with metabolic
dysfunction and obesity, has reached epidemic proportions worldwide. Although early …

Non-alcoholic fatty liver disease (NAFLD) includes a cluster of liver disorders ranging from
simple fatty liver to non-alcoholic steatohepatitis (NASH) and cirrhosis. Due to its liver and …

Deletion of the nuclear hormone receptor small heterodimer partner (Shp) ameliorates the
development of obesity and nonalcoholic steatohepatitis (NASH) in mice. Liver-specific SHP …

Non‐alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease that is becoming
more prevalent in concert with obesity and poor lifestyle habits. Although NAFLD is treatable …

The rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes has driven
a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat …

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging
from uncomplicated hepatic fat accumulation to a state of lobular inflammation and …